Plant-based platform Target pharmaceutical and biotech firms seeking decarbonized, scalable protein production could leverage Tiamat Sciences' plant-based platform to develop reagents and growth factors, potentially reducing material costs and development timelines.

Strategic partnerships Opportunity to partner with large biopharma suppliers and contract manufacturing organizations that demand scalable, sustainable and cost-efficient reagents, aligning with Tiamat’s plant-based production approach.

Executive expansion Leverage recent leadership hires in operations and strategy to position Tiamat as a growing, customer-centric provider; emphasize capabilities to accelerate onboarding and support for partner programs.

Funding validated Proven investor interest and multiple funding rounds signal market validation; approach growth-stage investors and potential co-development or grant-funded projects with strategic partners.

Niche biotech focus Focus on high-value protein reagents and growth factors for biotech and pharma customers, presenting a path to upsell with additional plant-produced reagents, assay components, and customized protein products.